61477-94-9

Pirrnenol hydrochloride is a long-lasting Class la antiarrhythmic agent introduced in Japan in 1994. The spectrum of antiarrhythmic activity of pirmenol includes atrial and ventricular arrhythmias of diverse etiology. In clinical trials, pirmenol was found effective in the short- and mid-term treatment of chronic premature ventricular beats, with or without underlying heart disease. In patients with supraventricular tachycardia, a single oral dose of pirmenol was highly effective in suppressing induction of tachycardia with adequate hemodynamic tolerance. Since pirmenol is highly effective by both intravenous and oral routes, it enables immediate suppression, prevention, or termination of cardiac arrhythmias and facilitates the transition to oral prophylactic therapy.

Warner-Lamber (U.S.A.)

Cardiac depressant (anti-arrhythmic).

Pirmavar (Parke-Davis);Plmenol.

Store at -20°C

The initial threshold screening level (ITSL) for pirmenol is 3 μg/m3 baaed on an annual averaging time.